BioAge Labs (BIOA) Cash & Equivalents (2023 - 2026)

BioAge Labs has disclosed Cash & Equivalents across 4 years of filings, most recently posting $241.8 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $241.8 million, down 6.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $241.8 million (down 6.0% YoY), and the FY2025 annual result was $188.9 million, down 46.69% from the prior year.
• Cash & Equivalents came in at $241.8 million for Q1 2026 at BioAge Labs, up from $188.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $354.3 million in Q4 2024 to a low of $21.6 million in Q4 2023.
• The 4-year median for Cash & Equivalents is $220.0 million (2025), against an average of $223.1 million.
• Across the five-year window, Cash & Equivalents surged 1537.17% in 2024 and plunged 46.69% in 2025, its largest moves.
• BioAge Labs' Cash & Equivalents stood at $21.6 million in 2023, then soared by 1537.17% to $354.3 million in 2024, then tumbled by 46.69% to $188.9 million in 2025, then advanced by 28.0% to $241.8 million in 2026.
• The last three Cash & Equivalents figures came in at $241.8 million (Q1 2026), $188.9 million (Q4 2025), and $215.6 million (Q3 2025), per Business Quant data.